- AstraZeneca's potential U.S. listing sparks investor interest, boosting shares by nearly 2%.
- Analysts predict a robust 40.25% upside with a target price of $100.29.
- GuruFocus estimates suggest a fair value of $91.33, indicating a 27.72% increase.
AstraZeneca (AZN, Financial) ADRs surged almost 2% amid speculation that CEO Pascal Soriot is considering relocating the company's stock listing from the U.K. to the U.S. Although there may be resistance from the company's board and the U.K. government, Soriot's motivation is driven by concerns over Europe's lag in pharmaceutical innovation. This potential shift underscores AstraZeneca's strategic focus on leveraging a more dynamic market environment.
Analyst Forecasts and Price Targets
According to 11 analysts, the average one-year target price for AstraZeneca PLC (AZN, Financial) comes in at $100.29. This suggests a significant potential upside of 40.25% from the current price of $71.51. Analysts have set a high estimate of $237.74 and a low estimate of $67.00. For more detailed forecast data, visit the AstraZeneca PLC (AZN) Forecast page.
Analyst Recommendations
The consensus recommendation from 13 brokerage firms places AstraZeneca PLC's (AZN, Financial) average brokerage rating at 1.8, signifying an "Outperform" status. This rating is on a scale from 1 to 5, where 1 represents a Strong Buy, and 5 indicates a Sell. This demonstrates analysts' confidence in AstraZeneca's market performance.
GF Value Estimation
GuruFocus estimates a GF Value for AstraZeneca PLC (AZN, Financial) at $91.33 within a year. This suggests a potential upside of 27.72% from the current market price of $71.51. The GF Value is an estimation of the stock's fair market value based on historical trading multiples, past business growth, and future business performance projections. For a comprehensive view, refer to the AstraZeneca PLC (AZN) Summary page.
